Companies Nektar Therapeutics
Nektar Therapeutics (NKTR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Nektar Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 16 peer CEOs
CEO pay, last three years
- $3,135,576FY2023
- $3,762,693FY2024
- $6,256,954FY2025
CEO total pay was $6,256,954 in fiscal 2025, up from $3,762,693 in fiscal 2024.
FY2025: salary $1,106,282 · bonus $0 · stock awards $942,081 · option awards $2,986,535
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Nektar Therapeutics in fiscal 2025?
As disclosed, Howard Robin (President and Chief Executive Officer) was the highest-paid executive at Nektar Therapeutics in fiscal 2025, with total compensation of $6,256,954.
How does Nektar Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Howard Robin's total compensation ranked at the 50th percentile of Nektar Therapeutics's disclosed peer group.
How did shareholders vote on Nektar Therapeutics's executive compensation?
As disclosed, 99.12% of shareholders supported Nektar Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Nektar Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Nektar Therapeutics reported total board compensation of $518,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Howard Robin | $1,106,282 | $0 | $942,081 | $2,986,535 | $1,106,282 | $0 | $115,774 | $6,256,954 |
| President and Chief Executive Officer | ||||||||
| Jonathan Zalevsky | 717,560 | 0 | 271,750 | 861,497 | 452,000 | 0 | 17,551 | 2,320,358 |
| Chief Research and Development Officer | ||||||||
| Sandra Gardiner | — | — | — | — | — | 0 | 686,400 | 686,400 |
| Interim Chief Financial Officer | ||||||||
| Mark Wilson | 645,950 | 0 | 0 | 0 | 0 | 0 | 21,951 | 667,901 |
| Former Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Howard Robin | $6,256,954 | $3,762,693 | $3,135,576 | ↑ +2,494,261 |
| Jonathan Zalevsky | 2,320,358 | 1,611,620 | 1,773,364 | ↑ +708,738 |
| Sandra Gardiner | 686,400 | 460,850 | 376,300 | ↑ +225,550 |
| Mark Wilson | 667,901 | 1,297,327 | 1,100,468 | ↓ −629,426 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The objective of our executive compensation program is to deliver compensation above industry median for exceptional performance and deliver compensation below the median in performance periods where the Company does not perform well.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Howard Robin | RSU | 2025-12-22 | — | — | 21,667 | — | $942,081 |
| Jonathan Zalevsky | RSU | 2025-12-22 | — | — | 6,250 | — | 271,750 |
| Jonathan Zalevsky | OPTION | 2025-12-22 | — | — | 25,000 | — | 861,497 |
| Howard Robin | OPTION | 2025-12-22 | — | — | 86,667 | — | 2,986,535 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Howard Robin | $942,081 | $0 | $2,986,535 | 0.0% |
| Jonathan Zalevsky | 271,750 | 0 | 861,497 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Wilson | Option | 773 | 326.85 | — |
| Jonathan Zalevsky | Option | 1,340 | 326.85 | — |
| Mark Wilson | Option | 2,386 | 326.85 | — |
| Howard Robin | Option | 2,973 | 326.85 | — |
| Mark Wilson | Option | 3,400 | 281.25 | — |
| Jonathan Zalevsky | PSU | 3,530 | — | 149,248 |
| Mark Wilson | Option | 4,476 | 198.3 | — |
| Jonathan Zalevsky | Option | 4,766 | 281.25 | — |
| Jonathan Zalevsky | Option | 4,770 | 326.85 | — |
| Mark Wilson | Option | 5,412 | 15.15 | — |
| Jonathan Zalevsky | Option | 5,568 | 7.48 | — |
| Jonathan Zalevsky | RSU | 6,250 | — | 264,250 |
| Jonathan Zalevsky | PSU | 6,250 | — | 264,250 |
| Jonathan Zalevsky | Option | 6,266 | 198.3 | — |
| Howard Robin | PSU | 8,403 | — | 355,279 |
| Jonathan Zalevsky | Option | 10,000 | 276.45 | — |
| Howard Robin | Option | 11,176 | 326.85 | — |
| Howard Robin | Option | 12,710 | 281.25 | — |
| Mark Wilson | Option | 14,424 | 7.48 | — |
| Howard Robin | Option | 14,916 | 198.3 | — |
| Jonathan Zalevsky | Option | 18,000 | 73.64 | — |
| Jonathan Zalevsky | Option | 18,760 | 15.15 | — |
| Howard Robin | RSU | 21,667 | — | 916,081 |
| Howard Robin | PSU | 21,667 | — | 916,081 |
| Mark Wilson | Option | 22,125 | 73.65 | — |
| Jonathan Zalevsky | Option | 25,000 | 15.15 | — |
| Jonathan Zalevsky | Option | 25,000 | 43.48 | — |
| Howard Robin | Option | 28,898 | 7.48 | — |
| Howard Robin | Option | 54,750 | 73.65 | — |
| Howard Robin | Option | 65,006 | 15.15 | — |
| Howard Robin | Option | 86,666 | 15.15 | — |
| Howard Robin | Option | 86,667 | 43.48 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert B. ChessIndependent · Board Chair | $130,500 | $0 | $358,876 | — | $0 | $489,376 |
| Roy A. WhitfieldIndependent · Lead Independent Director · Audit · Nominating and Corporate Governance (Chair) | 112,000 | 0 | 358,876 | — | 0 | 470,876 |
| R. Scott GreerIndependent · Audit (Chair) · Organization and Compensation · Nominating and Corporate Governance | 106,750 | 0 | 358,876 | — | 0 | 465,626 |
| Diana Brainard, M.DIndependent · Organization and Compensation (Chair) · Nominating and Corporate Governance | 86,750 | 0 | 358,876 | — | 0 | 445,626 |
| Jeff AjerIndependent · Audit · Organization and Compensation | 82,000 | 0 | 358,876 | — | 0 | 440,876 |
| Howard W. RobinEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $518,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $518,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Nektar Therapeutics as a peer
Companies that benchmark against NKTR
6 companies name NKTR as a compensation peer
- ADC Therapeutics SAADCTFY2025
- Coherus Oncology, Inc.CHRSFY2025
- ENANTA PHARMACEUTICALS INCENTAFY2025
- Kodiak Sciences Inc.KODFY2025
- PUMA BIOTECHNOLOGY, INC.PBYIFY2025
- RIGEL PHARMACEUTICALS INCRIGLFY2025
Each company listed discloses NKTR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NKTR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AMLX Amylyx PharmaceuticalsRLAY Relay TherapeuticsRCUS Arcus BiosciencesIDYA IDEAYA BiosciencesRZLT RezoluteATXS Astria TherapeuticsVERA Vera TherapeuticsCLDX Celldex TherapeuticsNTLA Intellia TherapeuticsCMPX Compass TherapeuticsVRDN Viridian TherapeuticsCRVS Corvus PharmaceuticalsOLMA Olema PharmaceuticalsDNTH Dianthus TherapeuticsKOD Kodiak SciencesPRAX Praxis Precision Medicines
Peer reciprocity
The companies Nektar Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics | 2025 | Marino Garcia | $630,000 | $0 | $9,450,952 | $519,750 | $10,614,702 |
| 2 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Ideaya Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 4 | Praxis Precision Medicines | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 5 | Corvus Pharmaceuticals | 2025 | Richard Miller | 36,566 | 0 | 6,989,000 | 0 | 7,031,566 |
| 6 | Vera Therapeutics | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 7 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 8 | Astria Therapeutics | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 9 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 10 | Rezolute | 2026 | Nevan Charles Elam | 655,000 | 3,220,720 | 1,358,972 | 0 | 5,711,410 |
| 11 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 12 | Compass Therapeutics | 2025 | Thomas Schuetz | 630,000 | 0 | 4,065,000 | 0 | 5,097,150 |
| 13 | Intellia Therapeutics | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 14 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 15 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 16 | Amylyx Pharmaceuticals | 2025 | Justin Klee | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 17 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Amylyx Pharmaceuticals | 106.5% | not disclosed | No | Pearl Meyer |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Astria Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Compass Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Corvus Pharmaceuticals | not disclosed | Option 100 | not disclosed | not disclosed |
| Dianthus Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Ideaya Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Intellia Therapeutics | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Kodiak Sciences | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| Praxis Precision Medicines | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Relay Therapeutics | 100% | Options 100 | not disclosed | Aon |
| Rezolute | not disclosed | not disclosed | not disclosed | not disclosed |
| Vera Therapeutics | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 18,154,226 | 161,005 | 111,111 | 99.12% | Passed |
| 2025 | 2025-05-23 | 96,965,611 | 4,097,449 | 1,090,722 | 95.95% | Passed |
| 2024 | 2024-06-05 | 87,037,178 | 6,730,748 | 6,227,905 | 92.82% | Passed |
| 2023 | 2023-06-08 | 114,458,620 | 19,391,723 | 787,269 | 85.01% | Passed |
| 2022 | 2022-06-08 | 130,982,076 | 26,344,578 | 311,570 | 83.09% | Passed |
| 2021 | 2021-06-10 | 151,749,699 | 5,030,154 | 175,462 | 96.68% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 99.12%a |
| 2025 | 2025-05-23 | 95.95%b |
| 2024 | 2024-06-05 | 92.82%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Howard W. Robin | Director | 2026-05-19 | D | 444 | $66 | $29,086 | Common, open-market sale | Form 4 ↗ |
| Jonathan Zalevsky | Chief R&D Officer | 2026-05-19 | D | 199 | 66 | 13,036 | Common, open-market sale | Form 4 ↗ |
| Jonathan Zalevsky | Chief R&D Officer | 2026-06-15 | D | 5,538 | 61 | 336,212 | Common, open-market sale | Form 4 ↗ |
| Howard W. Robin | Director | 2026-06-16 | D | 4,697 | 61 | 285,155 | Common, open-market sale | Form 4 ↗ |
| Howard W. Robin | Director | 2026-06-16 | D | 5,303 | 60 | 318,021 | Common, open-market sale | Form 4 ↗ |
| Howard W. Robin | Director | 2026-06-17 | D | 5,500 | 61 | 334,455 | Common, open-market sale | Form 4 ↗ |
| Howard W. Robin | Director | 2026-06-17 | D | 4,500 | 62 | 277,425 | Common, open-market sale | Form 4 ↗ |
| Jonathan Zalevsky | Chief R&D Officer | 2026-06-30 | D | 5,681 | 70 | 397,670 | Common | Form 4 ↗ |
| Jonathan Zalevsky | Chief R&D Officer | 2026-07-24 | A | 16,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Howard W. Robin | Director | 2026-07-24 | A | 57,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Zalevsky | Chief R&D Officer | 2026-08-18 | D | 186 | 72 | 13,388 | Common, open-market sale | Form 4 ↗ |
| Howard W. Robin | Director | 2026-08-18 | D | 418 | 72 | 30,088 | Common, open-market sale | Form 4 ↗ |
| Diana Brainard | Director | 2026-09-23 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert B. Chess | Director | 2026-09-23 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| R. Scott Greer | Director | 2026-09-23 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Roy A. Whitfield | Director | 2026-09-23 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Robert B. Chess | Director | 2026-09-23 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeff Ajer | Director | 2026-09-23 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Roy A. Whitfield | Director | 2026-09-23 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diana Brainard | Director | 2026-09-23 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeff Ajer | Director | 2026-09-23 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| R. Scott Greer | Director | 2026-09-23 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (61 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Howard Robin. DEF 14A, filed 2026-04-24. Section “SUMMARY COMPENSATION TABLE—FISCAL 2023-2025” · page 57. As printed: 6,256,954. View filing ↗
- Section 01, Jonathan Zalevsky. DEF 14A, filed 2026-04-24. Section “SUMMARY COMPENSATION TABLE—FISCAL 2023-2025” · page 57. As printed: 2,320,358. View filing ↗
- Section 01, Sandra Gardiner. DEF 14A, filed 2026-04-24. Section “SUMMARY COMPENSATION TABLE—FISCAL 2023-2025” · page 57. As printed: 686,400. View filing ↗
- Section 01, Mark Wilson. DEF 14A, filed 2026-04-24. Section “SUMMARY COMPENSATION TABLE—FISCAL 2023-2025” · page 57. As printed: 667,901. View filing ↗
- Section 03, Howard Robin RSU. DEF 14A, filed 2026-04-24. Section “GRANTS OF PLAN BASED AWARDS IN 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Zalevsky RSU. DEF 14A, filed 2026-04-24. Section “GRANTS OF PLAN BASED AWARDS IN 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Zalevsky OPTION. DEF 14A, filed 2026-04-24. Section “GRANTS OF PLAN BASED AWARDS IN 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Howard Robin OPTION. DEF 14A, filed 2026-04-24. Section “GRANTS OF PLAN BASED AWARDS IN 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-13. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Robert B. Chess. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 489,376. View filing ↗
- Section 08, Roy A. Whitfield. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 470,876. View filing ↗
- Section 08, R. Scott Greer. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 465,626. View filing ↗
- Section 08, Diana Brainard, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 445,626. View filing ↗
- Section 08, Jeff Ajer. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 440,876. View filing ↗
- Section 08, Howard W. Robin. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Howard W. Robin 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Zalevsky 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Zalevsky 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Zalevsky 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Zalevsky 2026-07-24. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-07-24. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Zalevsky 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Howard W. Robin 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diana Brainard 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Chess 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Scott Greer 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roy A. Whitfield 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Chess 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Ajer 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roy A. Whitfield 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diana Brainard 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff Ajer 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Scott Greer 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 99.12% (votes for as printed: 18,154,226). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-28. Item 5.07 · say-on-pay result. As reported: 95.95% (votes for as printed: 96,965,611). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 92.82% (votes for as printed: 87,037,178). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 518,000 + equity 0 + all other 0 = 518,000, summed across the director compensation table rows.
- Dianthus Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Dianthus Therapeutics's own proxy. As printed: 10,614,702. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Ideaya Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences's own proxy. As printed: 9,512,640. View filing ↗
- Praxis Precision Medicines, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Praxis Precision Medicines's own proxy. As printed: 8,708,648. View filing ↗
- Corvus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Corvus Pharmaceuticals's own proxy. As printed: 7,031,566. View filing ↗
- Vera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics's own proxy. As printed: 6,986,410. View filing ↗
- Viridian Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. View filing ↗
- Astria Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. View filing ↗
- Nektar Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Rezolute, Section 10b CEO total. DEF 14A, filed 2026-10-21. CEO total compensation as printed in Rezolute's own proxy. As printed: 5,711,410. View filing ↗
- Celldex Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. View filing ↗
- Compass Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Compass Therapeutics's own proxy. As printed: 5,097,150. View filing ↗
- Intellia Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. View filing ↗
- Relay Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. View filing ↗
- Olema Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. View filing ↗
- Amylyx Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals's own proxy. As printed: 2,719,807. View filing ↗
- Kodiak Sciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. View filing ↗
- Section 10a, Kodiak Sciences reciprocity. DEF 14A. Kodiak Sciences names Nektar Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗